Anne Moscona

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro
    Mohamad Aljofan
    Australian Animal Health Laboratory, CSIRO Livestock Industries, Geelong, Australia
    Virol J 6:187. 2009
  2. ncbi Medical management of influenza infection
    Anne Moscona
    Department of Pediatrics, Weill Cornell Medical College, New York, New York 10021, USA
    Annu Rev Med 59:397-413. 2008
  3. ncbi A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo
    Anne Moscona
    Departments of Pediatrics, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Infect Dis 202:234-41. 2010
  4. ncbi Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease
    Anne Moscona
    Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Invest 115:1688-98. 2005
  5. ncbi Neuraminidase inhibitors for influenza
    Anne Moscona
    Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA
    N Engl J Med 353:1363-73. 2005
  6. ncbi Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery
    Shohreh F Farzan
    Department of Pediatrics, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Biol Chem 286:37945-54. 2011
  7. ncbi Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity
    Laura M Palermo
    Department of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, 515 East 71st Street, 6th Floor, New York, NY 10021, USA
    J Virol 83:6900-8. 2009
  8. ncbi Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site
    Matteo Porotto
    Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, 515 East 71st Street, Box 309, New York, NY 10021, USA
    J Virol 80:1204-13. 2006
  9. ncbi Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites
    Matteo Porotto
    Department of Pediatrics, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl, New York, NY 10029, USA
    J Virol 78:13911-9. 2004
  10. ncbi Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein
    Matteo Porotto
    Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, 515 East 71st Street, 6th Floor, Box 309, New York, NY 10021, USA
    J Virol 85:12867-80. 2011

Research Grants

  1. Design of peptide entry inhibitors and delivery systems to target emerging henipa
    Anne Moscona; Fiscal Year: 2009
  2. Molecular basis for paramyxovirus entry
    Anne Moscona; Fiscal Year: 2010
  3. Design of peptide entry inhibitors and delivery systems to target emerging henipa
    Anne Moscona; Fiscal Year: 2010
  4. Molecular basis for paramyxovirus entry
    Anne Moscona; Fiscal Year: 2009
  5. MOLECULAR BASIS FOR PARAINFLUENZA 3 INFECTION
    Anne Moscona; Fiscal Year: 2007
  6. Fusion triggering by Hendra virus F protein: role of G
    Anne Moscona; Fiscal Year: 2004
  7. MOLECULAR BASIS FOR PARAINFLUENZA 3 INFECTION
    Anne Moscona; Fiscal Year: 2002
  8. Molecular basis for paramyxovirus entry
    Anne Moscona; Fiscal Year: 2010

Collaborators

Detail Information

Publications30

  1. ncbi Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro
    Mohamad Aljofan
    Australian Animal Health Laboratory, CSIRO Livestock Industries, Geelong, Australia
    Virol J 6:187. 2009
    ..Lead compounds were then further characterised to determine the median efficacy (IC50), cytotoxicity (CC50) and the in vitro therapeutic index in live virus and pseudotype assay formats...
  2. ncbi Medical management of influenza infection
    Anne Moscona
    Department of Pediatrics, Weill Cornell Medical College, New York, New York 10021, USA
    Annu Rev Med 59:397-413. 2008
    ....
  3. ncbi A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo
    Anne Moscona
    Departments of Pediatrics, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Infect Dis 202:234-41. 2010
    ..DAS181, a recombinant sialidase protein containing the catalytic domain of Actinomyces viscosus sialidase, removes cell surface sialic acid, and we proposed that it would inhibit HPIV infection...
  4. ncbi Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease
    Anne Moscona
    Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Invest 115:1688-98. 2005
    ..There are several steps during the process of binding, triggering, and fusion that are now understood at the molecular level, and each of these steps represents potential targets for interrupting infection...
  5. ncbi Neuraminidase inhibitors for influenza
    Anne Moscona
    Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA
    N Engl J Med 353:1363-73. 2005
  6. ncbi Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery
    Shohreh F Farzan
    Department of Pediatrics, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Biol Chem 286:37945-54. 2011
    ..This first evidence that activation of a paramyxovirus F can be specifically induced before the virus contacts its target cell suggests a new strategy with broad implications for the design of antiviral agents...
  7. ncbi Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity
    Laura M Palermo
    Department of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, 515 East 71st Street, 6th Floor, New York, NY 10021, USA
    J Virol 83:6900-8. 2009
    ..The finding that the dysregulation of F triggering prohibits successful infection in HAE cells suggests that antiviral strategies targeted to HN's F-triggering activity may have promise in vivo...
  8. ncbi Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site
    Matteo Porotto
    Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, 515 East 71st Street, Box 309, New York, NY 10021, USA
    J Virol 80:1204-13. 2006
    ..The finding that site II, once activated, shows higher avidity for receptor than site I, suggests paradigms for further elucidating the regulation of HN's multiple functions in the viral life cycle...
  9. ncbi Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites
    Matteo Porotto
    Department of Pediatrics, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl, New York, NY 10029, USA
    J Virol 78:13911-9. 2004
    ....
  10. ncbi Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein
    Matteo Porotto
    Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, 515 East 71st Street, 6th Floor, Box 309, New York, NY 10021, USA
    J Virol 85:12867-80. 2011
    ..This model has broad implications for the mechanism of paramyxovirus fusion and for strategies to prevent viral entry...
  11. ncbi The second receptor binding site of the globular head of the Newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion
    Matteo Porotto
    Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA
    J Virol 86:5730-41. 2012
    ..We suggest a general model for paramyxovirus fusion activation in which receptor engagement at site II plays an active role in F activation...
  12. ncbi A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism
    Matteo Porotto
    Department of Pediatrics, Weill Medical College of Cornell University, 515 East 71st Street, New York, NY 10021, USA
    J Virol 81:3216-28. 2007
    ....
  13. ncbi Viral entry inhibitors targeted to the membrane site of action
    Matteo Porotto
    Department of Pediatrics and Department of Microbiology and Immunology, Weill Medical College of Cornell University, 515 East 71st St, New York, NY 10021, USA
    J Virol 84:6760-8. 2010
    ..The cholesterol-tagged peptides on the cell surface create a protective antiviral shield, target the F protein directly at its site of action, and expand the potential utility of inhibitory peptides for paramyxoviruses...
  14. ncbi Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment
    Aparna Talekar
    Department of Pediatrics, Weill Medical College, Cornell University, New York, New York, United States of America
    PLoS ONE 7:e30538. 2012
    ..Our proposed strategy should contribute to the response capability for emerging infectious diseases, providing a way to initiate antiviral development immediately upon identifying novel viruses...
  15. ncbi Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir)
    Matthew Murrell
    Department of Pediatrics, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Virol 77:309-17. 2003
    ....
  16. ncbi Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry
    Matteo Porotto
    Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America
    PLoS Pathog 6:e1001168. 2010
    ..The in vivo efficacy of cholesterol-tagged peptides, and in particular their ability to penetrate the CNS, suggests that they are promising candidates for the prevention or therapy of infection by Nipah and other lethal paramyxoviruses...
  17. ncbi Regulation of paramyxovirus fusion activation: the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state
    Matteo Porotto
    Department of Pediatrics, Weill Medical College of Cornell University, New York, New York, USA
    J Virol 86:12838-48. 2012
    ..The results indicate that HN helps stabilize the prefusion state of F, and analysis of a stalk domain mutant HN reveals that the stalk domain of HN mediates the F-stabilization effect...
  18. ncbi Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus
    Kelly K Lee
    Department of Medicinal Chemistry and Biomolecular Structure and Design Program, University ofWashington, Seattle, Washington 98195, USA
    J Biol Chem 286:42141-9. 2011
    ..These results provide proof of concept for an antiviral strategy that is applicable to intracellularly fusing viruses, including known and emerging viral pathogens...
  19. ncbi Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion
    Matteo Porotto
    Department of Pediatrics, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Virol 77:3647-54. 2003
    ..C28a HN is the first parainfluenza virus variant found so far to be specifically defective in HN's F-triggering and fusion promotion functions and may contribute to our understanding of transmission of the activating signal from HN to F...
  20. ncbi Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein
    Matteo Porotto
    Department of Pediatrics, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl, New York, NY 10029, USA
    J Virol 79:2383-92. 2005
    ..Any particular HN's competence to promote F-mediated fusion depends on the balance between its inherent F-triggering efficacy and its receptor-attachment regulatory functions (binding and receptor cleavage)...
  21. ncbi Oseltamivir resistance--disabling our influenza defenses
    Anne Moscona
    Department of Pediatrics at Weill Medical College of Cornell University, New York, USA
    N Engl J Med 353:2633-6. 2005
  22. ncbi Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy
    Matteo Porotto
    Department of Pediatrics, Weill Medical College of Cornell University, 515 East 71st St, New York, NY 10021, USA
    J Virol 83:5148-55. 2009
    ..Given the established safety profile and broad experience with chloroquine in humans, the results described here provide an option for treating individuals infected by these deadly viruses...
  23. ncbi Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry
    Matteo Porotto
    Department of Pediatrics, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Biol Chem 287:778-93. 2012
    ..This first evidence for the sequence of initial events that lead to viral entry may indicate a new paradigm for understanding Paramyxovirus infection...
  24. ncbi Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II
    Laura M Palermo
    Department of Pediatrics, Weill Medical College of Cornell University, 515 East 71st St, Box 309, New York, NY 10021, USA
    J Virol 81:9152-61. 2007
    ..These mutations permit pH to modulate the binding and fusion processes of the virus, potentially providing regulation at specific stages of the viral life cycle...
  25. ncbi Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus
    Matteo Porotto
    Department of Pediatrics, Weill Medical College of Cornell University, New York, New York, United States of America
    PLoS ONE 6:e16874. 2011
    ..The use of protocells that interact with, but do not accumulate, viruses may provide significant advantages over current antiviral drugs, and this general approach may have wide potential for antiviral development...
  26. ncbi Oseltamivir-resistant influenza?
    Anne Moscona
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet 364:733-4. 2004
  27. ncbi Kinetic dependence of paramyxovirus entry inhibition
    Matteo Porotto
    Department of Pediatrics, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Virol 83:6947-51. 2009
    ..These results highlight new issues to be considered in developing strategies for fusion inhibitors...
  28. ncbi A daring treatment and a successful outcome: the need for targeted therapies for pediatric respiratory viruses
    Patricia DeLaMora
    Pediatr Transplant 11:121-3. 2007
  29. ncbi News about influenza B drug resistance that cannot be ignored
    Anne Moscona
    JAMA 297:1492-3. 2007
  30. ncbi Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus
    Mohamad Aljofan
    Australian Animal Health Laboratory, CSIRO Livestock Industries, Private Bag 24, Geelong 3220, Australia
    J Virol Methods 149:12-9. 2008
    ..The current experiments describe for the first time, a high throughput screening method amenable for direct assessment of live henipavirus antiviral drug activity...

Research Grants19

  1. Design of peptide entry inhibitors and delivery systems to target emerging henipa
    Anne Moscona; Fiscal Year: 2009
    ..abstract_text> ..
  2. Molecular basis for paramyxovirus entry
    Anne Moscona; Fiscal Year: 2010
    ..Newly identified mechanisms involved in the entry process could serve as potential new targets for antivirals to treat or prevent human respiratory diseases. ..
  3. Design of peptide entry inhibitors and delivery systems to target emerging henipa
    Anne Moscona; Fiscal Year: 2010
    ..abstract_text> ..
  4. Molecular basis for paramyxovirus entry
    Anne Moscona; Fiscal Year: 2009
    ..Newly identified mechanisms involved in the entry process could serve as potential new targets for antivirals to treat or prevent human respiratory diseases. ..
  5. MOLECULAR BASIS FOR PARAINFLUENZA 3 INFECTION
    Anne Moscona; Fiscal Year: 2007
    ..The proposed studies will lend insight into important molecular events in the life cycle of HPF3 and its interaction with the host, and will assist in the design of prevention and therapy. ..
  6. Fusion triggering by Hendra virus F protein: role of G
    Anne Moscona; Fiscal Year: 2004
    ..The results of the proposed studies will provide important new information about the fusion and entry mechanism of anemerging pathogen threat, and lead to development of strategies to block pathogenesis by this agent. ..
  7. MOLECULAR BASIS FOR PARAINFLUENZA 3 INFECTION
    Anne Moscona; Fiscal Year: 2002
    ..She will test the hypotheses that (A) avidity of virus-receptor interaction is a determinant of pathogenesis in the lung and (B) neuraminidase determines the outcome of infection in the lung as it does in cell culture. ..
  8. Molecular basis for paramyxovirus entry
    Anne Moscona; Fiscal Year: 2010
    ..Newly identified mechanisms involved in the entry process could serve as potential new targets for antivirals to treat or prevent human respiratory diseases. ..